Due to the complex physiological structure, microenvironment and multiple physiological
barriers, traditional anti‐cancer drugs are severely restricted from reaching the tumour site …

The exploitation of nanosized materials for the delivery of therapeutic agents is already a
clinical reality and still holds unrealized potential for the treatment of a variety of diseases …

The primary impediments in developing large antibodies as drugs against intracellular
targets involve their low transfection efficiency and suitable reversible encapsulation …

The current therapeutic antibody market in the US consists of 100 antibody-based products
and their market value is expected to explode beyond $300 billion by 2025. These therapies …

Background Effective methods to deliver therapeutic genes to solid tumors and improve their
bioavailability are the main challenges of current medical research on gene therapy. The …

Three kinds of coronaviruses are highly pathogenic to humans, and two of them mainly
infect humans through Angiotensin‐converting enzyme 2 (ACE2) receptors. Therefore …

Antibodies mediate the majority of their effects in the extracellular domain, or in intracellular
compartments isolated from the cytosol. Under a growing list of circumstances, however …

B-cell epitope prediction (BCEP) is the original subject of immunoinformatics (ie,
bioinformatics applied to immunology). This began with protein sequence analysis to identify …

Intracellular delivery of therapeutic antibodies is highly desirable but remains a challenge for
biomedical research and the pharmaceutical industry. Approximately two-thirds of disease …

Capicua (CIC)-rearranged sarcomas are an aggressive subset of undifferentiated round cell
sarcomas. CIC:: DUX4, the proto-typical CIC fusion oncoprotein is associated with rapid …